Edmonton Obesity Staging System (EOSS)
5-stage clinical staging system for obesity that incorporates comorbidities, functional limitations, and wellbeing — beyond BMI alone. Guides treatment intensity. Stage 0 = no complications; Stage 4 = end-stage complications.
Score interpretation
EOSS Stage 0 — no obesity-related complications; low metabolic risk despite elevated BMI
→ Dietary and lifestyle counselling; physical activity promotion; reassess annually; weight management not urgent but advisable for prevention
EOSS Stage 1 — subclinical risk factors; borderline values
→ Structured lifestyle intervention (diet + exercise); consider dietitian and physical activity programme; behavioural therapy; recheck metabolic markers in 6 months
EOSS Stage 2 — established medical and/or functional complications
→ Weight management programme with medical supervision; consider pharmacotherapy (orlistat, semaglutide); bariatric surgery assessment if BMI ≥35 with comorbidities; multidisciplinary team (physician, dietitian, psychologist, physiotherapist)
EOSS Stage 3 — severe obesity-related complications; significant functional impairment
→ Bariatric surgery recommended if eligible; intensive medical treatment; multidisciplinary bariatric team; prioritise surgical intervention over lifestyle-only approaches; address mental health comorbidities before surgery
EOSS Stage 4 — end-organ failure; severe disability
→ Palliative approach to weight management; focus on quality of life and symptom management; bariatric surgery high risk but may be considered in selected cases by specialist centres; maximise medical treatment of end-organ complications
Interpretation bands for the Edmonton Obesity Staging. Apply clinical judgement and local guidance.
References
- Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33(3):289–295.
Related
Curated clinical cross-links plus same-class fallbacks.
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Semaglutide · GLP-1 Receptor Agonist
- Liraglutide · GLP-1 Receptor Agonist
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Naltrexone with bupropion · Anti-obesity (combination)
- Levonorgestrel Intrauterine System · Progestogen-Only Intrauterine Device
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.